Primary Site >> Liver Cancer

Gene >> NAMPT

Journal: Cancer Prev Res (Phila). 2011 Dec;4(12):2092-100.
Title: Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Author: Ninomiya, Soranobu|Shimizu, Masahito|Imai, Kenji|Takai, Koji|Shiraki, Makoto|Hara, Takeshi|Tsurumi, Hisashi|Ishizaki, Sonoko|Moriwaki, Hisataka
PMID: 21952585
Journal: Dig Dis. 2012;30(5):508-13.
Title: Adipocytokines and hepatocellular carcinoma.
Author: Wieser, Verena|Moschen, Alexander R|Tilg, Herbert
PMID: 23108307
Journal: Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1659-71.
Title: Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan.
Author: Chen, Chi-Ling|Yang, Wei-Shiung|Yang, Hwai-I|Chen, Chuen-Fei|You, San-Lin|Wang, Li-Yu|Lu, Sheng-Nan|Liu, Chun-Jen|Kao, Jia-Horng|Chen, Pei-Jer|Chen, Ding-Shinn|Chen, Chien-Jen
PMID: 24895413
Journal: Rev Recent Clin Trials. 2014;9(3):134-40.
Title: Role of adipokines and cytokines in non-alcoholic fatty liver disease.
Author: Abenavoli, Ludovico|Peta, Valentina
PMID: 25514909
Journal: Biochem Biophys Res Commun. 2015 Mar 6;458(2):334-40.
Title: FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Author: Schuster, Susanne|Penke, Melanie|Gorski, Theresa|Gebhardt, Rolf|Weiss, Thomas S|Kiess, Wieland|Garten, Antje
PMID: 25656579
Journal: Mediators Inflamm. 2015;2015:392471.
Title: Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-kappaB activity and affects Nampt-dependent cell viability in Huh-7 cells.
Author: Lin, Yi-Ching|Wu, Hui-Chung|Liao, Chen-Chung|Chou, Yi-Chih|Pan, Shwu-Fen|Chiu, Chi-Ming
PMID: 25814788
Journal: Oncotarget. 2016 Nov 22;7(47):77968-77977.
Title: Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Author: Wu, Zhitong|Sun, Yifan|Huang, Yiyong|Zhu, Shengbo|Feng, Yi|Ye, Huifen|Liu, Chunming|Tang, Shifu
PMID: 27792999
Journal: Cytokine. 2017 Feb;90:54-59.
Title: Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Author: Tsai, I-Ting|Wang, Chao-Ping|Yu, Teng-Hung|Lu, Yung-Chuan|Lin, Chih-Wen|Lu, Li-Fen|Wu, Cheng-Ching|Chung, Fu-Mei|Lee, Yau-Jiunn|Hung, Wei-Chin|Hsu, Chia-Chang
PMID: 27770715
Journal: Oncotarget. 2017 Apr 4;8(14):23427-23435.
Title: Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Author: Sun, Yifan|Zhu, Shengbo|Wu, Zhitong|Huang, Yiyong|Liu, Chunming|Tang, Shifu|Wei, Lili
PMID: 28178643
Journal: Expert Rev Anticancer Ther. 2017 Apr;17(4):289-291.
Title: Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma?
Author: Garten, Antje|Schuster, Susanne|Penke, Melanie
PMID: 28271737
Journal: Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):48-52.
Title: Visfatin increases miR-21 to promote migration in HCC.
Author: Liang, Ninglin|Chen, Yongjun|Yang, Li|He, Suyu|Liu, Tianyu
PMID: 29808800